Actively Recruiting
Study of Metabolic, Transcriptomic and Proteomic Characteristics in Relapsed Glioblastoma
Led by University Hospital, Bordeaux · Updated on 2025-07-30
40
Participants Needed
1
Research Sites
103 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Glioblastomas are the most frequent and aggressive malignant tumors of the CNS in adults, with almost systematic relapse despite treatment with surgery followed by radio-chemotherapy (STUPP protocol). The aim of this study is to better characterize transcriptomic, proteomic and metabolic changes in relapsed glioblastoma compared to the initial tumor, in order to identify new prognostic markers and potential new therapeutic targets.
CONDITIONS
Official Title
Study of Metabolic, Transcriptomic and Proteomic Characteristics in Relapsed Glioblastoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age over 18 years
- Surgery for both primary and recurrent glioblastoma between 2005 and 2023 at the CHU de Bordeaux
You will not qualify if you...
- Received systemic therapy for a non-glioblastoma tumor
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
CHU de Bordeaux - Hôpital Saint-André, Service d'Oncologie Médicale
Bordeaux, France, 33000
Actively Recruiting
Research Team
M
Mathieu LARROQUETTE
CONTACT
J
Julien ENGELHARDT
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here